Executive record

Eric A. Adams

Director at InMed Pharmaceuticals Inc.

Follow
More
Challenge a Claim

Alpha ID: alpha:person:eric-a-adamsVersion: public-0As of: 2026-09-30

Not yet claimed10 published Claims4 sources
  • Director

Key Claims

Biography

Seasoned biopharmaceutical executive with over 30 years of experience in company and capital formation, global market development, mergers and acquisitions, and licensing. Served as CEO of EnGene Inc. from 2004-2011 and held senior roles at QLT Inc., Advanced Tissues Science Inc., Abbott Laboratories, and Fresenius AG.

Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.

Board service

Boards

Claims

Executive career

  1. 2025 to end not publishedExecutive title: President, Chief Executive Officer and Director · Organization not publishedINM 10-K executive officers
  2. Dates not publishedExecutive title: President and Chief Executive Officer · Organization not publishedINM DEF 14A director slate

Claims

Conflicts and accountability

Alpha has not published independence, related-party, proceedings or disciplinary Claims for this record. This is not a finding that none exist.

Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.

Evidence, history and coverage

Additional published Claims

Published evidence records

4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. INM DEF 14A director slate

    sec filing · Source published: Nov 3, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at InMed Pharmaceuticals Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. Open source

    sec proxy · Source published: Nov 3, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at InMed Pharmaceuticals Inc. · Claim reviewed: May 16, 2026

  3. INM 10-K executive officers

    sec filing · Source published: Sep 23, 2025 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at InMed Pharmaceuticals Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: President, Chief Executive Officer and Director · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  4. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of InMed Pharmaceuticals Inc. · Claim reviewed: May 16, 2026